PD64 Cost-Minimization Analysis And Psoriatic Arthritis: Insights From Health Technology Assessment Agency Recommendations

Hérica Núbia Cardoso Cirilo, Aldenora Maria Ximenes Rodrigues, Ana Carolina Peçanha Antonio, Bruna Santos, Cecília de Oliveira Carvalho Faria, Alicia Dornelles, Ida Schwartz · 2025

Read PD64 Cost-Minimization Analysis And Psoriatic Arthritis: Insights From Health Technology Assessment Agency Recommendations by Hérica Núbia Cardoso Cirilo, Aldenora Maria Ximenes Rodrigues, Ana Carolina Peçanha Antonio, Bruna Santos, Cecília de Oliveira Carvalho Faria, Alicia Dornelles, Ida Schwartz (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12768782.txt.

Description

Hérica Cirilo and co-authors survey how health technology agencies judge arthritis drugs on cost, in a 2025 conference paper. Cost-minimization analysis, the cheapest comparison method, is allowed only when trials prove two drugs truly equal, yet many appraisals fall short of that bar. The team reviewed agency reports on biological drugs for psoriatic arthritis published up to late 2024.

Cost-effectiveness and cost-utility studies dominated the appraisals. Three drugs tied as the most often judged, with nine evaluations each. Brazil's agency was the only one to use cost-minimization in every case, while Britain's NICE never used it. The authors stress how widely economic practice varies between agencies judging the same drugs.

Catalog record

CREATORHérica Núbia Cardoso Cirilo, Aldenora Maria Ximenes Rodrigues, Ana Carolina Peçanha Antonio, Bruna Santos, Cecília de Oliveira Carvalho Faria, Alicia Dornelles, Ida Schwartz
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE2 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC12768782

Browse the full library · About the Tower of Babel